BLTE
Belite Bio Inc ADRNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$6.84B
P/E Ratio
—
EPS
$-2.30
Beta
-1.22
52W High
$200.00
52W Low
$49.00
50-Day MA
$171.04
200-Day MA
$115.14
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
227.27
PEG Ratio
—
About Belite Bio Inc ADR
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, is engaged in the research and development of novel therapies targeting age-related atrophic macular degeneration and autosomal recessive stargardt diseases. The company is headquartered in San Diego, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-84.03M |
| Operating Margin | 0.00% |
| Return on Equity | -16.90% |
| Return on Assets | -11.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $19.59 |
| Price-to-Book | 8.65 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -35.61 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $39.97M |
| Float | $18.76M |
| % Insiders | 43.92% |
| % Institutions | 18.52% |
Analyst Ratings
Consensus ($211.50 target)
2
Strong Buy6
BuyData last updated: 4/7/2026